Baloxavir marboxil - 97%, high purity , Polymerase acidic protein inhibitor, CAS No.1985606-14-1, Polymerase acidic protein inhibitor

Item Number
B413378
Grouped product items
SKUSizeAvailabilityPrice Qty
B413378-1mg
1mg
In stock
$23.90
B413378-5mg
5mg
In stock
$97.90
B413378-10mg
10mg
In stock
$162.90
B413378-25mg
25mg
In stock
$303.90
B413378-50mg
50mg
In stock
$489.90
B413378-100mg
100mg
In stock
$815.90
B413378-250mg
250mg
In stock
$1,836.90

Antiviral Inhibitors

View related series
Anti-infection Influenza Virus

Basic Description

SynonymsF0001-1475 | S033188 | S-033188 | {[(3R)-2-[(2S)-12,13-difluoro-9-thiatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.0^{3,8}]tetradeca-10,13-dien-11-yl]oxy}methyl methyl carbonate | baloxavir
Specifications & PurityMoligand™, ≥97%
Biochemical and Physiological MechanismsBaloxavir marboxil, a cap-endonuclease inhibitor, is an antiviral drug.
Storage TempStore at -20°C,Argon charged
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionPolymerase acidic protein inhibitor
Product Description

Information

Baloxavir marboxil Baloxavir marboxil, a cap-endonuclease inhibitor, is an antiviral drug.


In vivo

Single-dose oral baloxavir marboxil is well tolerated, had a favorable safety profile, and has favorable pharmacokinetic characteristics, including a long half-life, supporting single oral dosing. In nonclinical studies, baloxavir marboxil is a prodrug and is converted to an active form, baloxavir acid, by hydrolysis. After single oral administration in rats and monkeys, plasma concentrations of baloxavir marboxil are below the lower limit of quantification (LLOQ) at all sampling points, and area under the plasma concentration-time curve of baloxavir acid increased dose proportionally. The major excretion route of radioactivity is via fecal excretion, whereas urinary excretion was low in rats and monkeys. Baloxavir marboxil has shown therapeutic activity in preclinical models of influenza A and B virus infections, including strains resistant to current antiviral agents. In murine models of seasonal influenza and avian influenza A(H5N1) or A(H7N9), orally administered baloxavir is associated with rapid reductions in pulmonary viral loads and decreased mortality.

Product Properties

ALogP2.602
Rotatable Bond6

Associated Targets(non-human)

Influenza A virus (11224 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PA Polymerase acidic protein (806 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

IUPAC Name [(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate
INCHI InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1
InChi Key RZVPBGBYGMDSBG-GGAORHGYSA-N
Canonical SMILES COC(=O)OCOC1=C2C(=O)N3CCOCC3N(N2C=CC1=O)C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F
Isomeric SMILES COC(=O)OCOC1=C2C(=O)N3CCOC[C@H]3N(N2C=CC1=O)[C@H]4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F
PubChem CID 124081896
Molecular Weight 571.55

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

7 results found

Lot NumberCertificate TypeDateItem
H2219082Certificate of AnalysisJun 18, 2022 B413378
H2219083Certificate of AnalysisJun 18, 2022 B413378
H2219084Certificate of AnalysisJun 18, 2022 B413378
H2219087Certificate of AnalysisJun 18, 2022 B413378
H2219088Certificate of AnalysisJun 18, 2022 B413378
H2219089Certificate of AnalysisJun 18, 2022 B413378
H2219090Certificate of AnalysisJun 18, 2022 B413378

Chemical and Physical Properties

SolubilitySolubility (25°C) In vitro DMSO: 100 mg/mL (174.96 mM); Ethanol: 7 mg/mL (12.24 mM); Water: Insoluble;
DMSO(mg / mL) Max Solubility100
DMSO(mM) Max Solubility174.962820400665
Water(mg / mL) Max Solubility<1

Safety and Hazards(GHS)

Pictogram(s) GHS09
Hazard Statements

H411:Toxic to aquatic life with long lasting effects

Precautionary Statements

P273:Avoid release to the environment.

P501:Dispose of contents/container to ...

P391:Collect spillage.

Related Documents

References

1. Ivashchenko AA, Mitkin OD, Jones JC, Nikitin AV, Koryakova AG, Ryakhovskiy A, Karapetian RN, Kravchenko DV, Aladinskiy V, Leneva IA et al..  (2020)  Non-rigid Diarylmethyl Analogs of Baloxavir as Cap-Dependent Endonuclease Inhibitors of Influenza Viruses..  J Med Chem,  63  (17): (9403-9420).  [PMID:32787099] [10.1021/op500134e]
2. Takashita E, Morita H, Ogawa R, Nakamura K, Fujisaki S, Shirakura M, Kuwahara T, Kishida N, Watanabe S, Odagiri T.  (2018)  Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil..  Front Microbiol,  (13): (3026).  [PMID:30574137] [10.1021/op500134e]
3. Abraham GM, Morton JB, Saravolatz LD.  (2020)  Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza..  Clin Infect Dis,  71  (7): (1790-1794).  [PMID:32020174] [10.1021/op500134e]

Solution Calculators